




FIG. 1

Heavy Chain (HC) and Light Chain (LC) Sequences of KL2B997 and KL2B1251

<u>KL2B997</u>	
HC (SEQ ID NO. 472)	
QVQLQESGPQ LVPSETLSL	TCTVSGGSIS SYVSWIRQPGKGLEWIGY IYYSGSTNYN PSLKSRVTIS VDTSKNQFSL
KLSSVTAADT AVYYCAGTTI	FGVTFPNFY GMDVMGGTT VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE
PVTYSWNSGA LTSGVHTFPA	VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KKVEPKSCDK <u>THTQSGSGSH</u>
<u>HHHHGSGLP ETGG</u>	
LC (SEQ ID NO. 473)	
DIQMTQSPSF LSASVGDRVT	ITCRASQGIS SYLAWYQQKPGKAPKFLIYA ASTLQSGVPS RFSGSGSGTE FTLTISSLPQ
EDFATYYCQQ LNSYPLTFGG	GTKVEIKRTV AAPSVFIFFP SDEQLKSGTA SWVCLLNIFY PREAKVQMKV DNALQSGNSQ
ESVTEQDSKD STYSLSSLT	LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGE
<u>KL2B1251</u>	
HC (SEQ ID NO. 474)	
QVQLQESGPQ LVPSETLSL	TCTVSGGSIS SYVSWIRQPGKGLEWIGY IYYSGSTNYN PSLKSRVTIS VDTSKNQFSL
KLSSVTAADT AVYYCAGTTI	FGVTFPNFY GMDVMGGTT VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE
PVTYSWNSGA LTSGVHTFPA	VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KKVEPKSC
LC (SEQ ID NO. 475)	
DIQMTQSPSF LSASVGDRVT	ITCRASQGIS SYLAWYQQKPGKAPKFLIYA ASTLQSGVPS RFSGSGSGTE FTLTISSLPQ
EDFATYYCQQ LNSYPLTFGG	GTKVEIKRTV AAPSVFIFFP SDEQLKSGTA SWVCLLNIFY PREAKVQMKV DNALQSGNSQ
ESVTEQDSKD STYSLSSLT	LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGE

FIG. 2




FIG. 4




FIG. 3A




FIG. 3B

Individual body weights of and doses administered to male cynomolgus monkeys given single IV doses of KL2B1251-NOTA (in Group 1) and KL2B1251-TOPA (in Group 2)

Animal	Group	Body Weight (kg)	Dose Route	Actual Dose Concentration (mg/mL)	Target Dose Level (mg/kg)	Actual Dose Volume (mL/animal)	Calculated Dose Administered (mg/kg)	
							(mg/animal)	
0101	1	4.8	IV	0.784	1	4.8	3.76	0.784
0102	1	4.8	IV	0.784	1	4.8	3.76	0.784
0103	1	2.8	IV	0.784	1	2.8	2.20	0.784
0104	1	4.4	IV	0.784	1	4.4	3.45	0.784
0201	2	3.4	IV	1.03	1	3.4	3.50	1.03
0202	2	4.7	IV	1.03	1	4.7	4.84	1.03
0203	2	3.1	IV	1.03	1	3.1	3.19	1.03
0204	2	3.3	IV	1.03	1	3.3	3.40	1.03
IV Intravenous; given as a slow bolus injection over approximately 1 minute.								


FIG. 5

Individual and Mean (SD) Serum Pharmacokinetic Estimates of KL2B1251-NOTA (in Group 1) and KL2B1251-TOPA (in Group 2) Following a Single IV Dose of 1 mg/kg in Male Cynomolgus Monkeys

Group	ID	C _{max} (ng/mL)	AUC _{0-∞} (ng·day/mL)	AUC _{0-t} (ng·day/mL)	V _Z (mL/kg)	CL (mL/day/kg)	T _{1/2} (day)
Group 1	101	23022.95	1786.98	1796.61	464.24	556.6	0.58
	102	21253.62	1430.23	1439.25	609.28	694.81	0.61
	103	19911.69	1155.4	1160.51	796.97	861.69	0.64
	104	22034.81	1359.64	1366.49	623.67	731.80	0.59
	Mean	21555.77	1433.06	1440.71	623.54	711.23	0.60
	SD	1313.57	263.15	265.01	136.21	125.49	0.03
Group 2	201	22224.62	985.93	989.86	1106.42	1010.25	0.76
	202	18140.25	1018.39	1091.11	2120.84	916.50	1.60
	203	14576.70	661.19	665.65	1161.32	1502.29	0.54
	204	12793.75	600.47	603.57	1243.17	1656.82	0.52
	Mean	16933.83	816.49	837.55	1407.94	1271.46	0.85
	SD	4169.1	216.22	239.3	478.58	363.32	0.51

FIG. 6

Mean (SD) Serum Concentration-Time Profiles Following a Single IV Dose of 1 mg/kg of KL2B1251-NOTA (in Group 1) and KL2B1251-TOPA (in Group 2) in Male Cynomolgus Monkeys



Note: Data points with concentrations below the lowest quantifiable concentration (0.25 ng/mL) are not shown in the graph.

FIG. 7